gestion

Metastatic colorectal cancer (mCRC) having the V600E BRAF mutation is associated with poor prognosis. However, currently it is not proven that the presence of this mutation is an indicator of benefit to treatment with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies A recent meta-analysis and systematic review of randomized controlled trials published until July 2014 […]

Breast/ovarian hereditary cancer 2 gene panel (BRCA1 and BRCA2) Female carriers of the mutation, in either BRCA gene, have 60% to 80% lifetime risk of developing breast cancer and 20% to 50% of ovarian cancer, as well as an increased risk of developing other cancers. Family history and age are the most important criteria for